This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer

This study has been completed.
Information provided by:
Taiho Pharmaceutical Co., Ltd. Identifier:
First received: September 12, 2005
Last updated: July 6, 2011
Last verified: July 2011
This is an open-label, multicenter, three arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of S-1 alone compared with S-1 plus CDDP, and S-1 plus CDDP compared with 5-FU plus CDDP in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be randomly assigned (1:1:1) to S-1 (Arm A), S-1/CDDP (Arm B) or 5-FU/CDDP (Arm C). Patients will be stratified to achieve balanced distribution of patients to each arm according to following stratifications, performance status (0, 1, or 2), the number of metastatic sites (1 vs >1), prior gastrectomy, and center.

Condition Intervention Phase
Gastric Cancer Drug: S-1 Drug: S-1 plus CDDP Drug: 5-FU plus CDDP Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter, Randomized, 3 Arm Study of S-1 Compared With S-1/CDDP, or S-1/CDDP Compared With 5-FU/CDDP in Patients With Advanced Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease

Resource links provided by NLM:

Further study details as provided by Taiho Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Response rate [ Time Frame: every course for first three courses, then every other course ]

Secondary Outcome Measures:
  • Safety profile, time to treatment failure [ Time Frame: any time ]

Estimated Enrollment: 180
Study Start Date: July 2005
Study Completion Date: June 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: S-1
S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
Active Comparator: 2
S-1 plus CDDP
Drug: S-1 plus CDDP
S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
Active Comparator: 3
5-FU plus CDDP
Drug: 5-FU plus CDDP
5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non-prior chemotherapy treated advanced gastric adenocarcinoma
  • Age 18 and over
  • Performance status 0, 1, or 2 (ECOG)
  • Life expectancy 3 months
  • Hematopoietic WBC lower limit of normal-12,000/mm^3 Absolute granulocyte count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL
  • Hepatic AST and ALT ≤ 100 U/L ALP ≤ 2 times upper limit of normal (ULN) Bilirubin ≤ 1.5 mg/dL
  • Renal Plasma creatinine ≤ ULN Creatinine clearance ≥ 60 mL/min

Exclusion Criteria:

  • Interstitial pneumonia, pulmonary fibrosis
  • Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure
  • Intestinal paralysis, intestinal obstruction, uncontrollable diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00202969

China, Beijing
Beijing Cancer Hospital
No.52 Fu-Cheng Road, Hai-dian District, Beijing, China
Sponsors and Collaborators
Taiho Pharmaceutical Co., Ltd.
Principal Investigator: Jin Maolin, MD Beijing Cancer Hospital
  More Information

Responsible Party: Taiho Pharmaceutical Co., Ltd. Identifier: NCT00202969     History of Changes
Other Study ID Numbers: SC101
Study First Received: September 12, 2005
Last Updated: July 6, 2011

Keywords provided by Taiho Pharmaceutical Co., Ltd.:
Stomach cancer

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents processed this record on August 18, 2017